Rafael Pharmaceuticals Announces Expansion into Austria, South Korea and Spain of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

August 1, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search